Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line by Dr. David Gerber
Dr West
Author
Howard (Jack) West, MD

Dramatic benefit from EGFR inhibition in lung cancer with EGFR mutationsDr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.

 

[powerpress]

ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line Audio Podcast

Next Previous link

Previous PostNext Post

Related Content

Recent Comments

JOIN THE CONVERSATION
ROS 1
By JanineT GRACE … on
Hi siigs, I'm sorry you're…
By JanineT GRACE … on
Tomorrow Saturday, Oct. 25, 2025
By JanineT GRACE … on
Blood Cancers OncTalk-Live, Free, Learn Sat. Oct. 25
By JanineT GRACE … on